Section of Cardiology, Baylor College of Medicine, Houston, Texas, USA.
J Cardiovasc Electrophysiol. 2010 Sep;21(9):1064-70. doi: 10.1111/j.1540-8167.2010.01774.x.
Atrial fibrillation (AF) is a common arrhythmia and is associated with significant morbidity and mortality. The pathogenesis of AF remains incompletely understood and management remains a difficult task. Over the past decade there has been accumulating evidence implicating inflammation in the pathogenesis of AF. Inflammation appears to play a significant role in the initiation and perpetuation of AF as well as the prothrombotic state associated with AF. Inflammatory biomarkers (C-reactive protein and interleukin-6) have been shown to be associated with the future development, recurrence and burden of AF, and the likelihood of successful cardioversion. Therapies directed at attenuating the inflammatory burden appear promising. Animal and clinical studies have evaluated statins, angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers, and corticosteroids for the treatment or prevention of AF. The purpose of this review is to provide current evidence on the relationship between inflammation and AF and potential therapies available to modulate the inflammatory state in AF.
心房颤动（AF）是一种常见的心律失常，与显著的发病率和死亡率相关。AF 的发病机制仍不完全清楚，其管理仍然是一项艰巨的任务。在过去的十年中，越来越多的证据表明炎症在 AF 的发病机制中起作用。炎症似乎在 AF 的发生和持续以及与 AF 相关的血栓形成状态中起着重要作用。炎症生物标志物（C 反应蛋白和白细胞介素 6）已被证明与 AF 的未来发展、复发和负担以及电复律的成功率相关。针对减轻炎症负担的治疗方法似乎很有前途。动物和临床研究已经评估了他汀类药物、血管紧张素转换酶抑制剂/血管紧张素 II 受体阻滞剂和皮质类固醇类药物用于 AF 的治疗或预防。本文的目的是提供目前关于炎症与 AF 之间关系的证据，并探讨潜在的治疗方法来调节 AF 中的炎症状态。
